Evidence map›Paper›PMID 36143205›Full record

ArticleJournal of personalized medicine2022

The Effect of SARS-CoV-2 Vaccination on B-Cell Phenotype in Systemic Sclerosis Patients.

Chiara Pellicano, Amalia Colalillo, Valerio Basile, Mariapaola Marino, Umberto Basile, Francesca La Gualana, Ivano Mezzaroma, Marcella Visentini, Edoardo Rosato

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Chiara PellicanoDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Amalia ColalilloDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Valerio BasileClinical Pathology Unit and Cancer Biobank, Department of Research and Advanced Technologies, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Mariapaola MarinoDepartment of Translational Medicine and Surgery, Section of General Pathology, "A. Gemelli" IRCCS, Catholic University of the Sacred Heart, 00168 Rome, Italy.ORCID 0000-0001-9155-6378
Umberto BasileDepartment of Laboratory and Infectious Disease Sciences, "A. Gemelli" IRCCS, Catholic University of the Sacred Heart, 00168 Rome, Italy.ORCID 0000-0002-8328-2570
Francesca La GualanaDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Ivano MezzaromaDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-2855-6425
Marcella VisentiniDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Edoardo RosatoDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-7417-8093
Sapienza University of Rome · ITUniversità Cattolica del Sacro Cuore · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveto assess the influence of SARS-CoV-2 mRNA vaccine on B-cell phenotypes in systemic sclerosis (SSc).

methodsperipheral blood B-cell subpopulations were evaluated before (t1) and 3 months (t3) after the second dose of vaccine in 28 SSc patients. Peripheral blood B-cell subpopulations were evaluated in 21 healthy controls (HCs) only at t1. Anti-spike IgG levels were evaluated at t3 in both cohorts.

resultsSSc patients presented higher naive, double-negative, and CD21

conclusionsSARS-CoV-2 mRNA vaccine response is normal in SSc patients not undergoing immunosuppressive therapy. The normal number of naive B cells is a positive marker of antibody response. The increased percentage of CD21

Indexed as

B cellsCOVID-19humoral responsemRNA vaccinesystemic sclerosis

Identifiers

PMID36143205
PMCPMC9500778
OpenAlexW4294308233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.